Business
PainReform Provides Business Update for the Six Months Ended June 30, 2025
TEL AVIV, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of AI-driven solar analytics technologies, today provided a business update for the six months ended June 30, 2025. Key Highlights: Completed majority investment in LayerBio, adding OcuRing™-K, a breakthrough dropless cataract therapy targeting a ~$9B global marketAdvanced PRF-110 with ongoing R&D fol
About this update from Prf Technologies Ltd.
[{"type":"image","alt":"PainReform Ltd","displaySize":"","headline":null,"caption":"PainReform Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":283,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/b87767806c4b38224443db9a93a3dd0a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8rnf4Sfc87De6ZQ.vLH_qw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b87767806c4b38224443db9a93a3dd0a","width":283,"height":122}},"lazy":false},{"type":"text","content":"TEL AVIV, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of AI-driven solar analytics technologies, today provided a business update for the six months ended June 30, 2025.","length":313,"tagName":"p"},{"type":"text","content":"Key Highlights:","length":15,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Completed majority investment in LayerBio, adding OcuRing™-K, a breakthrough dropless cataract therapy targeting a ~$9B global market","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"Advanced PRF-110 with ongoing R&D following partially positive efficacy signals in postoperative pain","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"Expanded DeepSolar with completion of Smart Energy Management app, acceptance into NVIDIA Connect Program, and successful completion of a 92MW pilot with Econergy that advanced into the Company’s first commercial agreement","length":222,"tagName":"p"}]},{"val":[{"type":"text","content":"Reduced net loss to $2.3M vs. $12.8M in prior-year period; maintained $3.5M cash and positive working capital of $1.5M","length":118,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":578,"olType":false},{"type":"text","content":"Ehud Geller, Chairman and interim Chief Executive Officer of PainReform, stated, "The first half of 2025 has been transformational for PainReform as we advanced our dual strategy in specialty pharmaceuticals and renewable energy technologies. On the pharmaceutical side, we strengthened our pipeline with the acquisition of a majority interest in LayerBio and its OcuRing™-K platform, a breakthrough ‘dropless’ therapy designed to address post-surgical pain and inflammation ...